CANO - Cano Health, Inc.
NYSE
->
Healthcare
->
Medical Care Facilities
Miami,
United States
Type: Equity
CANO price evolution
CANO
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $87.5 | $107.16 | $242.22 | $233.82 |
| Inventory | ||||
| Total current assets | $144.7 | $166.34 | $313.69 | $340.75 |
| Long term investments | ||||
| Property, plant & equipment | $243.8 | $303.91 | $310.79 | $309.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1211.9 | $1707.32 | $1944.38 | $1928.93 |
| Current liabilities | ||||
| Accounts payable | $135.9 | $124.82 | $115.23 | $105.73 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $365.9 | $336.93 | $213.91 | $208.44 |
| Long term debt | $959 | $930 | $1016.44 | $1001.17 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1334 | $1560.62 | $1663.51 | $1676.3 |
| Shareholders' equity | ||||
| Retained earnings | -$715.4 | -$454.94 | -$314.18 | -$286.03 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.04 | |||
| Short term investments | ||||
| Net receivables | $233.82 | $133.43 | $67.35 | $49.25 |
| Inventory | $1.11 | $0.92 | $0.65 | |
| Total current assets | $340.75 | $317.24 | $1.22 | $82.88 |
| Long term investments | ||||
| Property, plant & equipment | $309.22 | $217.43 | $38.13 | $19.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $690.31 | $0.05 | ||
| Total investments | ||||
| Total assets | $1928.93 | $2143.54 | $691.53 | $0.05 |
| Current liabilities | ||||
| Accounts payable | $105.73 | $72.77 | $31.37 | $12.72 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $208.44 | $161.04 | $2.18 | $0.05 |
| Long term debt | $1001.17 | $918.78 | $459.2 | $134.03 |
| Total noncurrent liabilities | $684.35 | |||
| Total debt | ||||
| Total liabilities | $1676.3 | $1824.81 | $686.53 | $0.05 |
| Shareholders' equity | ||||
| Retained earnings | -$286.03 | -$78.76 | -$28.89 | -$0.01 |
| Other shareholder equity | -$0.13 | -$0.13 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $665.03 | $689.37 | ||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $696.47 | $720.42 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$1.25 | $0.81 | ||
| Interest expense | -$82.17 | $17.04 | ||
| Net income | ||||
| Net income | -$54.23 | -$5.33 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1609.37 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1744.56 | $5.71 | ||
| Operating income | -$5.71 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | |||
| Interest expense | $31.63 | |||
| Net income | ||||
| Net income | -$18.02 | -$28.88 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$48.15 | -$29.27 | -$13.46 | -$1131.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$6.76 | -$3.88 | $0.54 | $1389.14 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$139.07 | -$115.32 | -$50.12 | $129.36 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | |
|---|---|---|---|---|
| Net income | -$28.88 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$1.15 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1131.25 | -$690 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1389.14 | $692.19 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $129.36 | $1.04 | ||
News
Fundamentals
| Market cap | $1.27M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 5.40M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 26.24% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.40 |
| Quick ratio | N/A |